Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model

PURPOSE: To evaluate the molecular, pharmacokinetic, and pharmacological properties of three anti-vascular endothelial growth factor (VEGF) agents—aflibercept, brolucizumab, and ranibizumab—and to provide a prediction of the optimal design of an intravitreal VEGF challenge in rabbits to assess the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Schubert, William, Terjung, Carsten, Rafique, Ashique, Romano, Carmelo, Ellinger, Philipp, Rittenhouse, Kay D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Retina
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617509/
https://www.ncbi.nlm.nih.gov/pubmed/36282118
http://dx.doi.org/10.1167/tvst.11.10.36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617509/
https://www.ncbi.nlm.nih.gov/pubmed/36282118
http://dx.doi.org/10.1167/tvst.11.10.36

Ejemplares similares